DB
GLUE icon

Dmitry Balyasny’s Monte Rosa Therapeutics GLUE Stock Holding History

Dmitry Balyasny’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.81M Sell
198,895
-57,836
-23% -$1.09M 0.01% 1389
2026
Q1 		$4.22M Buy
+256,731
New +$4.91M 0.01% 1437
2025
Q4 		– Sell
-408,540
Closed -$3.03M – 3264
2025
Q3 		$3.03M Buy
+408,540
New +$2.16M ﹤0.01% 1611
2024
Q1 		– Sell
-38,802
Closed -$219K – 2801
2023
Q4 		$219K Buy
+38,802
New +$152K ﹤0.01% 2284
2022
Q4 		– Sell
-19,031
Closed -$155K – 2945
2022
Q3 		$155K Buy
+19,031
New +$175K ﹤0.01% 2353

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dmitry Balyasny's GLUE Position: Q2 2026 in Review

Dmitry Balyasny reduced its Monte Rosa Therapeutics (GLUE) stake by 23% in Q2 2026, selling an estimated $1.09M and leaving 198,895 shares worth $4.81M. The position accounts for 0.01% of the portfolio, ranked #1389.

Dmitry Balyasny first reported a position in GLUE in Q3 2022 and has held it in 5 quarters since. 191 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Dmitry Balyasny held 198,895 shares of Monte Rosa Therapeutics worth $4.81M as of Q2 2026.
  • Dmitry Balyasny sold 57,836 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.09M.
  • Monte Rosa Therapeutics made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1389 holding.
  • Dmitry Balyasny first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.